A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States

A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States

Background: The National Comprehensive Cancer Network recommends that patients with hormone receptor-positive early breast cancer be considered for adjuvant endocrine therapy (ET) after primary treatment like surgical excision. Adjuvant chemotherapy (CT) use primarily depends on risk of recurrence....

Full description

Bibliographic Details
Main Authors: Brown, J. (Author), Burris, H. (Author), Hamilton, E. (Author), Jones, S. (Author), Method, M. (Author), Misch, A. (Author), Picard, S. (Author), Scardo, S. (Author), Schlauch, D. (Author), Spigel, D. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Breast neoplasm
Diagnostic test
Early breast cancer
HR+ breast cancer
Ki-67
Ki-67 index
Retrospective study
Treatment pattern
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items